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a patient’s multiple prior admissions. Our objective is to
develop a model that predicts future admissions based on
left ventricular ejection fraction (LVEF) and the occur-
rence of a CHF admission in the preceding quarter.
Another objective is to use this model to examine, in a
managed care setting, the cost-beneﬁt of the following
CHF management strategies: ACE inhibitor therapy, beta
blocker therapy, CHF disease management, and inten-
sive case management. METHODS: We constructed a
Markov model to project the medical and non-medical
costs for a cohort of CHF patients in a commercially
insured population. The model deﬁnes four disease states
based on LVEF status (normal vs. low) and a prior admis-
sion (yes vs. no) in the preceding quarter. The probabil-
ity of a future admission depends on the patient’s disease
state as well as age and gender. Plan-speciﬁc CHF admis-
sion probabilities were calibrated using claims analyses.
Each intervention is assumed to change health service 
utilization patterns and improve survival. Cost-beneﬁt 
is expressed as net savings in medical and non-medical
costs. RESULTS: For a population of 100,000 commer-
cially insured individuals, CHF case rate and medical
costs are predicted to increase steadily over the next 5
years. Intensive case management appears to be the most
cost-beneﬁcial intervention, with an estimated per
member per month (PMPM) net savings of $0.11 in the
ﬁrst year. Beta blocker therapy is expected to save $0.08
in the ﬁrst year, while ACE inhibitors and CHF disease
management show net positive savings starting year 2. All
interventions remain cost-beneﬁcial when non-medical
savings are eliminated from the analyses. CONCLU-
SIONS: The four CHF management strategies modeled
are not only effective in improving clinical outcomes; they
are also predicted to be cost-beneﬁcial in a managed care
setting.
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OBJECTIVES: Coronary artery disease (CAD) is the
second most important disease resulting in mortality 
in Hong Kong. The most severe manifestation is acute
myocardial infarction (AMI). Both treatment and cardiac
rehabilitation for AMI are costly. Cost of management of
AMI is an important baseline information for better plan-
ning under scarce allocation of medical resources. The
present study aims to evaluate the cost of management of
explicit Q-wave AMI in a local public hospital in Hong
Kong. METHODS: A retrospective study was performed
on patients admitted to the United Christian Hospital.
The study cohort consisted of one hundred patients
admitted to Coronary Care Unit who were aged 18 year
old or above with a diagnosis of Q-wave AMI from 1
January 2000 to 31 December 2000. Cost items studied
included hospital stay, outpatient clinic visits, diagnostic
tests, medications, and percutaneous coronary interven-
tions. RESULTS: Ninety-eight case notes (2 case note
were incomplete) were evaluated. The average annual
medical cost per patient for AMI management in this 
population was USD $8990 (1 US $ = 7.8HK$). The total
annual cost per patient per year increased with the com-
plexity of the disease—from USD $7320 for non-fatal MI
without procedure, USD $10,963 for non-fatal MI with
angiogram, to USD $12,030 for non-fatal MI with pro-
cedure. Based on the local epidemiological data, the
prevalence rate of CAD is 2.2% and assuming 3% of
patients may experience AMI with medical care, the esti-
mated total cost of AMI management in Hong Kong was
USD $45 million per year, or 0.5% of the 2000–01
healthcare expenditure. CONCLUSIONS: The present
study provides information of the cost of AMI manage-
ment in Hong Kong. It conﬁrms that AMI management
is a signiﬁcant burden to the healthcare budget. Public
awareness on CAD and implementation of appropriate
health measures should be reinforced.
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OBJECTIVE: To determine the impact of acute rheumatic
fever (ARF) and chronic rheumatic heart disease (CRHD)
on hospital expenditure in the United States. METHODS:
This study analyzed data from the Healthcare Cost and
Utilization Project (2000) funded by the Agency for
Healthcare Research and Quality. Hospitalizations due 
to ARF and CRHD were identiﬁed using ICD-9 codes
390–398 as principal diagnoses. RESULTS: In 2000,
there were approximately 1226 and 44,659 hospitaliza-
tions due to ARF and CRHD, respectively. Females
accounted for about 58% of all hospitalizations due to
ARF, and 63% due to CRHD. The elderly aged 65 years
and older accounted for 74% of the hospitalizations due
to CRHD, followed by adults aged 35–64 years (24%).
The two most common comorbid conditions associated
with CRHD were atrial ﬁbrillation (49%) and hyperten-
sion (34%). The two most common procedures per-
formed during CRHD hospitalizations were
extracorporeal circulation for open heart surgery (10%)
and diagnostic ultrasound of the heart (7%). The mean
(and median) length of hospital stay for ARF and CRHD
was 7.5 (5) and 7.9 (6) days, respectively. Average charge
per hospital stay was about $29,500 for ARF and
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$38,700 for CRHD. Total annual hospitalization charges
for ARF and CRHD were estimated at $1.9 billion in year
2002 US dollars. CONCLUSIONS: Rheumatic fever 
and its sequelae CRHD represent a signiﬁcant economic
burden in the US. Total annual hospitalization charges
estimated for ARF and CRHD are substantially higher
than the recent estimate by the Institute of Medicine (Vac-
cines for the 21st Century, A Tool for Decisionmaking,
2000) for all group A streptococcus-associated hospital-
izations (<$100 million).
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OBJECTIVES: Our objective is to demonstrate software
technology that predicts the toll of smoking and deter-
mines the return on investment (ROI) of tobacco control
programs in a managed care setting. METHODS: We
developed a software application that incorporates a
Markov model to track changes in smoking status in 
6-month cycles over 20 years. Important features of a
managed care setting such as member turnover and plan
beneﬁt design are incorporated in the model. A curvi-
linear function of quit duration was used to estimate
disease risk for former smokers. The model predicts all
medical costs associated with a given population by esti-
mating costs for 39 conditions, 17 of which are smoking
related. It calculates case rates and cost per case by
smoking status for each condition using epidemiological
concepts of relative risk and smoking-attributable frac-
tion. Additionally, non-medical costs associated with
smoking are estimated from the employer and societal
perspectives. RESULTS: The smoking prevalence in a
commercially insured health plan of 980,292 members is
predicted to increase to 21% in year 2022 from 16% in
2002, if there is no change in smoking behavior. Current
smokers are predicted to contribute 36% of the medical
costs of smoking related conditions at year 2002 and
increase their share to 44% in 2022. Relative to all
medical costs, this is equivalent to 19% in 2002 and 28%
in 2022. The incremental non-medical costs per current
smoker employee are estimated to be $2047 in 2002.
CONCLUSIONS: MediSave Smoking Cessation enables
rapid prediction of the baseline tobacco burden on
medical as well as non-medical costs in a managed care
context, and permits estimation of the ROI of interven-
tion programs. Its user-friendly format facilitates sensi-
tivity analyses of various program characteristics. As
such, it is a useful tool to build the business case for
tobacco control programs.
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OBJECTIVES: Our objective is to estimate the medical
and non-medical savings associated with two smoking
cessation interventions in a Minnesota health plan using
a new predictive technology, and to determine the return
on investment (ROI). METHODS: We developed a
Markov model to simulate the smoking behaviors, health
outcomes and impact of tobacco control programs in a
managed care setting. We integrated the model into a soft-
ware application called MediSave and used it to deter-
mine the combined impact of two interventions, which
include coverage of smoking cessation pharmaceutical
aids (such as buproprion or nicotine substitutes) and
physician advice. Program participation and cost data
were provided by the health plan. Intervention quit rates
were derived from literature. Medical savings result from
the higher quit rate associated with the interventions.
Non-medical savings accrue to the employer because of
reduction in smoking breaks as well as illness days. The
ROI is calculated as the net (medical and non-medical)
savings over program costs. RESULTS: In a commercially
insured population of 980,292 members, the combined
interventions generate positive net savings of $0.02 per
member per month (PMPM) at the end of ﬁrst year. They
generate gross savings of $0.17 PMPM, only 33% of
which are from medical savings. First year ROI is esti-
mated to be 16% and predicted to increase signiﬁcantly
over the next 20 years. Eliminating non-medical savings
from the analysis will result in a negative ROI in the ﬁrst
year but will not affect the positive net savings past year
5. CONCLUSIONS: MediSave Smoking Cessation is an
effective tool in making the business case for tobacco
control programs. In our study, the combined impact of
pharmaceuticals and physician advice is cost-beneﬁcial.
The interventions produce substantial non-medical
savings in the short term and generate signiﬁcant medical
savings in the long term.
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OBJECTIVE: Two relatively common myths regarding
the impact of obesity on quality of life are: 1) women are
